What Procyrion does

Procyrion, Inc. is a privately held, clinical-stage medical device company founded in 2005 and headquartered in Houston, Texas, that is developing Aortix™, a catheter-deployed percutaneous mechanical circulatory support (pMCS) device intended for hospitalized heart failure patients with concurrent renal dysfunction (cardiorenal syndrome). Aortix is placed in the descending thoracic aorta between the heart and renal arteries and uses a proprietary fluid entrainment mechanism — high-velocity jets that accelerate native blood flow — to pump blood without a valve, simultaneously reducing cardiac workload by decreasing afterload and increasing renal perfusion. The device is less than 6mm in diameter, delivers up to 7 days of circulatory support, and is designed for percutaneous deployment in under 10 minutes via femoral access using self-expanding nickel-titanium anchors.

The company's business model is a pre-revenue medical device hardware sales model contingent on regulatory approval. Procyrion has not yet commercialized Aortix and does not have publicly disclosed pricing; the device remains investigational in the U.S. and is limited to clinical investigations in the European Union. The company has raised over $133.7 million cumulatively across grants, Series C ($16M, 2018), Series D ($30M, 2019), and Series E ($57.7M, 2024), led by Fannin Partners and Bluebird Ventures, and holds FDA Breakthrough Device Designation (July 2019) and ISO 13485:2016 certification. It is currently enrolling the DRAIN-HF pivotal IDE trial to support a future PMA submission.

Procyrion is preparing for commercialization through enterprise hospital sales into cardiac catheterization labs and mechanical circulatory support programs, supplemented by KOL engagement at major cardiovascular conferences and clinical publications. The intended customers are hospitals treating acute decompensated heart failure (ADHF) patients — a market exceeding 6 million U.S. adults affected by heart failure, over 1.8 million HF hospitalizations annually, and $100+ billion in global annual spend — with primary focus on the cardiorenal syndrome subpopulation where up to 64% of ADHF hospitalizations involve renal dysfunction. The company operates with 11-50 employees, draws leadership from former Abbott/St. Jude Medical, Thoratec, Silk Road Medical, and Medtronic executives, and is led by President & CEO Eric S. Fain, MD.

Name

Procyrion

Legal name

Procyrion, Inc.

Website

https://procyrion.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Procyrion is a clinical-stage Houston-based medical device company developing Aortix™, a catheter-deployed percutaneous circulatory support pump that simultaneously unloads the heart and perfuses the kidneys to treat acute decompensated heart failure patients with cardiorenal syndrome.

Ownership category

akta.pro rank

Product category

Cardiac Assist Devices (Percutaneous Mechanical Circulatory Support)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Percutaneous circulatory support
• Cardiac assist devices
• Heart failure therapy
• Mechanical circulatory support
• Cardiorenal syndrome treatment

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Procyrion is a pre-commercial medical device company developing the Aortix pMCS device. The company has not yet generated revenue as the device is in clinical development and not approved for sale. Upon regulatory approval, the company will commercialize through hospital/healthcare system sales channels.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Procyrion develops the Aortix™ percutaneous mechanical circulatory support (pMCS) device — a catheter-deployed intra-aortic pump placed in the descending thoracic aorta that uses a valveless fluid entrainment mechanism to reduce cardiac workload and increase renal perfusion. The investigational device is designed to treat acute decompensated heart failure (ADHF) patients with cardiorenal syndrome who have failed medical therapy. The device is currently in clinical development (DRAIN-HF pivotal IDE trial) and is not approved for commercial sale in any country.

Product overview

Procyrion is developing a single core product, the Aortix™ percutaneous mechanical circulatory support (pMCS) device, which is a catheter-deployed intra-aortic pump technology. The Aortix system is designed to simultaneously rest the heart by reducing afterload and improve renal perfusion by accelerating blood flow to the kidneys. The device uses a unique fluid entrainment mechanism that pumps blood without requiring a valve, and is designed for deployment in less than 10 minutes via a percutaneous catheter procedure. The product is currently in clinical development (IDE pivotal trial phase) and is not yet approved for commercial sale.

Differentiator

Problem solved

Functional benefit

Brands

• Aortix™: Percutaneous mechanical circulatory support (pMCS) device designed to treat heart failure patients who are too sick for medication alone. The device is placed in the descending thoracic aorta via catheter and harnesses fluid entrainment to pump blood without the need for a valve.

Products and services

• Aortix™ Percutaneous Mechanical Circulatory Support (pMCS) Device A catheter-deployed intra-aortic pump placed in the descending thoracic aorta that uses a valveless fluid entrainment mechanism to reduce cardiac workload (afterload) and increase renal perfusion simultaneously. Designed for percutaneous deployment in under 10 minutes via the femoral artery, with self-expanding nickel-titanium anchors securing the pump to the aortic wall. Provides up to 7 days of circulatory support and is intended for hospitalized acute decompensated heart failure (ADHF) patients with worsening renal function (cardiorenal syndrome) who have failed medical therapy. Currently in clinical development (DRAIN-HF pivotal IDE trial); investigational and not approved for sale in any country.

Quantifiable outcome

• Reduced heart workload by almost 40% in pre-clinical studies
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Abiomed (Abbott): Acquired by Abbott in 2023, Abiomed markets the Impella family of percutaneous mechanical circulatory support devices, which is the most directly competing catheter-based pMCS platform to Aortix in the heart failure and cardiogenic shock space.

Broad incumbents

• Teleflex: Through its Arrow division, Teleflex manufactures intra-aortic balloon pumps (IABP), the established standard-of-care for percutaneous mechanical circulatory support that Aortix aims to displace in cardiorenal syndrome patients.
• Getinge (Maquet): Getinge's Maquet division provides intra-aortic balloon counterpulsation therapy and ECMO systems, making it an established incumbent in the broader percutaneous mechanical circulatory support market where Aortix competes.
• LivaNova: LivaNova acquired the TandemHeart pMCS platform and offers mechanical circulatory support solutions for cardiogenic shock and heart failure, competing in the same cath-lab-based pMCS space as Aortix.
• Abbott: Beyond Impella, Abbott offers HeartMate left ventricular assist devices and a broad cardiovascular portfolio including IABP, making it a major incumbent across the entire mechanical circulatory support landscape in which Procyrion operates.
• Fresenius Medical Care (Xenios): Fresenius acquired Xenios to provide ECMO and cardiopulmonary support technologies, making it a broad incumbent in mechanical circulatory support adjacent to Aortix's cath-lab-based pMCS focus.
• Terumo: Terumo offers advanced cardiovascular and interventional products including circulatory support devices and catheter-based technologies, making it a relevant broad incumbent in the cath-lab interventional space where Aortix will commercialize.
• Edwards Lifesciences: Edwards Lifesciences is a leader in structural heart and heart failure therapies, and is developing transcatheter heart failure solutions that may overlap with or compete against Aortix in the advanced heart failure treatment space.

Emerging players

• Cardiobridge: Cardiobridge developed the Reitan catheter-based circulatory support system for percutaneous support, representing another emerging European pMCS technology with overlapping indication space in acute heart failure and cardiorenal applications.
• Magenta Medical: Magenta Medical is developing transcatheter heart pump technologies for acute heart failure with similar miniaturization and percutaneous delivery goals as Aortix, making it an emerging peer in the next-generation pMCS category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/procyrion
• LinkedInlinkedin.com/company/2422446

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Procyrion